Aktis Oncology (AKTS) investor relations material

Strategic vision and platform innovation

• Focused on expanding radiopharmaceuticals for cancer, targeting patients lacking current options.

• Developed novel miniprotein binders to deliver high radiation doses to tumors while minimizing exposure to normal tissues.

• Platform enables targeting a broad array of tumor antigens with high affinity and selectivity, aiming for bone marrow protection.

• Built an end-to-end supply chain, including in-house CMC and a new GMP manufacturing facility opening by year-end.

• Secured multiple actinium supply deals, ensuring robust access to key radioisotopes.

Lead programs and clinical progress

• Lead program 1189 targets Nectin-4, expressed in multiple tumor types with no current radiopharmaceutical options.

• Initial clinical imaging data show high tumor uptake, favorable dosimetry, and low bone marrow exposure.

• Ongoing phase I-B dose escalation study for 1189, with substantive data update expected in Q1 next year.

• Second program 2519 targets B7-H3, with preliminary human imaging data showing promising tumor uptake and rapid normal tissue clearance.

• IND filing for 2519 planned in the first half of the year, with imaging and dosimetry data to be presented mid-year.

Competitive positioning and development strategy

• 1189 positioned post-Padcev in urothelial cancer, addressing a gap in the treatment paradigm.

• B7-H3 program aims for first-in-class status, with broad development across lung, prostate, and other solid tumors.

• Both programs use BOIN backfill design to optimize dose and accelerate signal detection.

• Pipeline includes additional assets beyond Nectin-4 and B7-H3, targeting both validated and novel tumor antigens.

• Business development remains a priority, with a focus on retaining key economic rights for lead assets.